Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ agency announces new pharmacy tools

This article was originally published in The Tan Sheet

Executive Summary

The Department of Health and Human Services' Agency for Healthcare Research and Quality offers two new tools for pharmacies aimed at better serving people with limited health literacy, AHRQ announces Oct. 30. The tools - "Is Our Pharmacy Meeting Patients' Needs? A Pharmacy Health Literacy Assessment Tool User's Guide" and "Strategies to Improve Communication between Pharmacy Staff and Patients: A Training Program for Pharmacy Staff" - are geared at raising awareness of health literacy limitations and training staff on ways to better assist pharmacy patients, according to a press release. AHRQ cites a study that found people with limited health literacy are more likely to be unable to identify their OTC as well as prescription medications, difficulty understanding instructions and less likely to understand potential side effects than the more health literate 1("The Tan Sheet" Dec. 4, 2006, p. 9). The tools are a result of an Emory University study funded by AHRQ and the Robert Wood Johnson Foundation...

You may also be interested in...



Labels May Need Explicit References To Consequences Of Misuse – Ganley

Frequent occasions of drug-label comprehension not predicting appropriate use suggest that OTC drug labels need more explicit language, FDA's Office of Nonprescription Products director says

J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Topics

UsernamePublicRestriction

Register

PS101123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel